Zydus buys Assertio for $166m to scale US in FY27

Deal announced: all-cash acquisition of Assertio

Zydus Lifesciences said it will acquire US-based Assertio Holdings through its subsidiary Zydus Worldwide DMCC and an acquisition vehicle, Zara Merger Sub Inc. The transaction is an all-cash deal valued at about $166.4 million, which the company pegged at around ₹1,570 crore. The offer price is $13.50 per share in cash for all outstanding shares of Assertio common stock. Assertio is listed on Nasdaq under the ticker ASRT. The announcement was released on Wednesday, dated May 13, 2026 (08:30 ET).

Why the acquisition matters for Zydus’ US strategy

Zydus said the acquisition provides a ready-made commercial platform in the United States. It also strengthens the company’s specialty pharmaceutical presence, particularly in pain management and oncology-support therapies. The deal gives Zydus direct access to Assertio’s marketing and distribution network in the world’s largest pharmaceutical market. Zydus said it plans to leverage Assertio’s commercial infrastructure and oncology relationships to expand its specialty oncology presence in the US. The stated focus is on building a broader specialty footprint rather than only manufacturing-led growth.

What Assertio sells in the US

Assertio markets a portfolio of branded prescription products in the United States. Zydus highlighted oncology-support as a key area where the platform can be used for expansion. The product examples cited include Rolvedon, a long-acting treatment used to reduce infection risk in cancer patients undergoing chemotherapy. The presence of established commercial operations was positioned as a core strategic fit for Zydus. The transaction is intended to add a branded-drugs commercial layer to Zydus’ US business.

Offer price and premiums over prior bids

Zydus’ $13.50-per-share cash offer represents a 30.6% premium to Garda Therapeutics’ earlier $18-per-share offer announced on April 8, 2026. It also implies a 7.8% premium to Garda’s revised $11.80-per-share bid announced on May 4, 2026. Assertio also disclosed that the Zydus offer is 75.8% higher than the company’s unaffected closing share price on March 20, 2026, which was before unusual trading activity and sharp share-price movement began. Assertio’s board determined that the Zydus proposal constituted a “Superior Proposal” under the revised Garda merger agreement.

Why the Garda agreement was terminated

The transaction emerged after Assertio’s board abandoned its earlier merger agreement with Garda Therapeutics. The board concluded Zydus’ offer provided better value and stronger execution certainty. Assertio said the Zydus bid had no financing contingencies and was fully guaranteed by a Zydus entity. It also said the offer requires no third-party financing, giving Assertio direct recourse if there is a breach or failure to close. Following the board’s decision, Assertio was authorized to terminate the Garda agreement announced on May 4, 2026.

How the transaction is structured

The deal is structured as a tender offer followed by a second-step merger. Under the terms outlined by Assertio, Zydus will promptly commence a tender offer to acquire all outstanding shares for $13.50 per share in cash. The board unanimously recommended that Assertio stockholders tender their shares into the transaction. The closing is subject to customary conditions, including tender of a majority of Assertio’s outstanding shares. One report also said the transaction is subject to minimum tender and minimum balance sheet requirements, and cited a seller termination fee of $1.26 million in case of termination.

Expected timeline and listing status after close

Zydus said the transaction is expected to close in FY27, subject to customary closing conditions, including majority tender. Assertio’s announcement separately said the deal is expected to close in the second quarter of 2026, subject to customary conditions. Assertio also said no regulatory approvals are expected to be required. After successful completion of the tender offer, Zydus will acquire any remaining shares through a second-step merger at the same price. Once completed, Assertio will be delisted and its common stock will no longer be listed on Nasdaq.

Management commentary from Zydus

Zydus Lifesciences Managing Director Sharvil Patel said the transaction would strengthen the company’s specialty and oncology footprint in the US. He also said it would help Zydus build “differentiated, durable specialty businesses globally.” The statement tied the acquisition to expanding specialty capabilities using Assertio’s commercial infrastructure. The emphasis was on gaining a scaled US platform rather than entering the market from scratch.

Key deal terms at a glance

Market impact and what investors should track

For Zydus, the deal adds a US-based branded prescription portfolio and a commercial platform that can support specialty expansion. For Assertio shareholders, the all-cash structure provides an exit at a stated premium to earlier bids and to the unaffected price referenced by the company. Investors will watch tender participation levels since closing is tied to the tender of a majority of outstanding shares. Another focus area is the closing timeline, with communications referencing FY27 and separately the second quarter of 2026. Assertio said it expects to file a Form 8-K summarising key terms, and also expects to file a Schedule 14D-9 in connection with the tender offer.

Conclusion

Zydus’ planned $166.4 million acquisition of Assertio positions the company to strengthen its US specialty presence in pain and oncology-support therapies using an existing commercial setup. The board-backed deal replaces Assertio’s earlier agreement with Garda Therapeutics and is structured as a tender offer followed by a merger. The transaction remains subject to customary closing conditions, including majority tender of shares. The next milestones will be the formal commencement of the tender offer and Assertio’s filings with the US SEC detailing the process and terms.